Company intelligence / Profile preview

CytoPathfinder

Ownership: Private
Development stage: Other

Overview

CytoPathfinder has developed a proprietary solid-phase transfection platform that enables efficient delivery of nucleic acids into various cell types. Their technology is used in drug discovery and pharmacogenomics research by pharmaceutical companies and academic partners. The company has contributed to multiple genome-wide screening studies for cancer drug development and viral disease mechanisms but does not have its own clinical-stage therapeutics pipeline[1][2].

Therapeutic areas: Infectious DiseasesOncology
Modalities: Small interfering RNAPlasmid DNAAntisense oligonucleotide (inferred from siRNA and nucleic acid focus)
Industry: Drug Discovery Services

Partnerships

Takeda Pharmaceutical (licensed siRNA solid-phase transfection technology for internal use in 2008)PhoenixBio Co., Ltd. (joint work on in vitro siRNA assay kits since 2019)

Beyond the preview

Go deeper on CytoPathfinder.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CytoPathfinder.

Explore the full profile